Intrinsiqq
Progyny Inc. logo

Progyny Inc. Quality Score

PGNY

⊜ Compare
Quality89

Growth and business quality are strong, valuation is the relative weak spot (avg 65/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
32.7x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
90/100
12.9x

Under 20x cash flow, well covered

Revenue Growth
100/100
13.6%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
23.3%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
100/100
-17.8%

Shrinking >2%, active buybacks

Margin Trend
100/100
+5.6pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$210M

Net cash position, no leverage concern

2022
$189M
$8.00M
2023
$371M
$19.0M
2024
$228M
$19.0M
2025
$310M
$28.0M
TTM
$237M
$27.0M
CashDebt
Return on Capital
60/100
13.6%

10–15%, respectable returns

Customize WeightsPremiumUpgrade

Progyny (PGNY) quality: score, margins and returns

Progyny (PGNY) scores 89/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 8.6% operating margins and 13.6% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Progyny (PGNY) a high-quality business?+

Progyny scores 89 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 8.6% operating margin and a 13.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Progyny's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PGNY's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Progyny scores well and where it falls behind.

What is Progyny's return on invested capital (ROIC)?+

Progyny earns about 13.6% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PGNY's margins and growth on this scorecard to judge durability.

How profitable is Progyny?+

Progyny runs an operating margin of about 8.6% and a net margin of about 6.0%. Revenue has grown at roughly 30.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 8 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Services-Misc Health & Allied Services, NEC · Pick stocks to compare with PGNY

CompareIntrinsic value
SHCSotera Health Company
$16.39+2.25%57
VMDViemed Healthcare Inc.
$10.11+6.93%82
QIPTQuipt Home Medical Corp.
No recent price11
FMSFresenius Medical Care AG - Depositary Receipt
$23.19+6.72%58
AGLAgilon Health Inc.
$96.23+9.61%28
CONConcentra Group Holdings Inc.
$41.06+2.27%57
ACHCAcadia Healthcare Company, Inc.
$32.44+9.52%19
GHGuardant Health Inc.
$168.58-3.67%30

Held by ETFs

PGNY is in 88 US ETFs. The largest of them, with PGNY's weight in each:

Spot a number that looks wrong? Check it in PGNY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PGNY

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.